Tafasitamab Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Tafasitamab comprises 25 peer-reviewed publications across 14 journals, 4 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell, and Lymphoma, B-Cell, Marginal Zone. Most recent publication: Anti-CD19 antibody tafasitamab therapy for relapsed or refractory diffuse large B-cell lymphoma: a case series., Anticancer Drugs, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G, Duell J, González Barca E, et al. · Lancet Oncol · 2020
    PubMed: PMID 32511983 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse
  2. CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.
    Duell J, Obr A, Augustin M, et al. · Leuk Lymphoma · 2022
    PubMed: PMID 34779360 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse
  3. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Duell J, Maddocks KJ, González-Barca E, et al. · Haematologica · 2021
    PubMed: PMID 34196165 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse
  4. Anti-CD19 antibody tafasitamab therapy for relapsed or refractory diffuse large B-cell lymphoma: a case series.
    You J, Chen W, Yan Z, et al. · Anticancer Drugs · 2026
    PubMed: PMID 41176775 · NCT05552937
  5. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
    Sehn LH, Hübel K, Luminari S, et al. · Lancet · 2026
    PubMed: PMID 41360064 · NCT04680052 (InMIND) · Lymphoma, B-Cell, Marginal Zone
  6. Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
    Roschewski M, Kurtz DM, Westin JR, et al. · J Clin Oncol · 2025
    PubMed: PMID 40802906 · NCT04134936 · Lymphoma, Large B-Cell, Diffuse
  7. International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma.
    Jelicic J, Juul-Jensen K, Bukumiric Z, et al. · Clin Lymphoma Myeloma Leuk · 2026
    PubMed: PMID 40993016 · NCT04824092 (frontMIND) · Lymphoma, Large B-Cell, Diffuse
  8. Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.
    Izutsu K, Fukuhara N, Yuda J, et al. · Cancer Sci · 2026
    PubMed: PMID 41563911 · NCT04661007 (J-MIND) · Lymphoma, Large B-Cell, Diffuse

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02763319
B-MIND
Lymphoma, Large B-Cell, DiffuseKaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Natural Killer Cell Count-Low Subgroup
up to 46.5 months
Rituximab + Bendamustine5.60 months
Tafasitamab + Bendamustine5.60 months
NCT02763319
B-MIND
Lymphoma, Large B-Cell, DiffuseKaplan-Meier Estimate of Progression-Free Survival by Independent Radiology/Clinical Review Committee Assessment in the Overall Population
up to 41.4 months
Rituximab + Bendamustine8.30 months
Tafasitamab + Bendamustine7.10 months
NCT04680052
InMIND
Lymphoma, B-Cell, Marginal ZoneFL Population: Kaplan-Meier Estimates of PFS by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented PD, or Death From Any Cause, Whichever Occurred First
up to 2 years
FL: Placebo + Rituximab + Lenalidomide31.8 percent probability
FL: Placebo + Rituximab + Lenalidomide78.2 percent probability
FL: Placebo + Rituximab + Lenalidomide54.0 percent probability
FL: Placebo + Rituximab + Lenalidomide38.5 percent probability
FL: Tafasitamab + Rituximab + Lenalidomide79.0 percent probability
FL: Tafasitamab + Rituximab + Lenalidomide41.7 percent probability
FL: Tafasitamab + Rituximab + Lenalidomide61.9 percent probability
FL: Tafasitamab + Rituximab + Lenalidomide92.4 percent probability
NCT04680052
InMIND
Lymphoma, B-Cell, Marginal ZoneFL Population: Progression-free Survival (PFS) by Investigator Assessment, Using the Lugano 2014 Criteria, Defined as the Time From Randomization to the First Documented Disease Progression (PD), or Death From Any Cause, Whichever Occurred First
up to approximately 34 months
FL: Placebo + Rituximab + Lenalidomide13.93 months
FL: Tafasitamab + Rituximab + Lenalidomide22.37 months

Publications by year

2002–2026: 25 publications.

2002
1
2010
1
2016
1
2018
1
2020
2
2021
2
2022
7
2023
4
2024
1
2025
1
2026
4

Publications by indication

Lymphoma, Large B-Cell, Diffuse (22)

  • International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma.
    Clin Lymphoma Myeloma Leuk · 2026 · PMID 40993016 · NCT04824092
  • Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.
    Cancer Sci · 2026 · PMID 41563911 · NCT04661007
  • Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
    J Clin Oncol · 2025 · PMID 40802906 · NCT04134936
  • Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
    Haematologica · 2024 · PMID 37646664 · NCT02399085
  • Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
    J Clin Oncol · 2023 · PMID 35952327 · NCT04978584

Leukemia, Lymphocytic, Chronic, B-Cell (1)

  • Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
    Leuk Lymphoma · 2022 · PMID 34414843 · NCT02639910

Lymphoma, B-Cell, Marginal Zone (1)

  • Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
    Lancet · 2026 · PMID 41360064 · NCT04680052

Publications by journal

Trial-results highlights

In the B-MIND study (NCT02763319), which investigated diffuse large B-cell lymphoma, the Kaplan-Meier estimate of progression-free survival (PFS) by independent review in the natural killer cell count-low subgroup was assessed. The rituximab plus bendamustine arm reported a median PFS of 5.60 months, while the tafasitamab plus bendamustine arm also reported a median PFS of 5.60 months. In the overall population of this study, the median PFS was 8.30 months for the rituximab plus bendamustine arm and 7.10 months for the tafasitamab plus bendamustine arm. These assessments were conducted for up to 46.5 months in the subgroup and up to 41.4 months in the overall population.

For B-cell marginal zone lymphoma, the InMIND study (NCT04680052) evaluated outcomes in the follicular lymphoma (FL) population. Progression-free survival by investigator assessment was evaluated for up to approximately 34 months. The placebo plus rituximab plus lenalidomide arm reported a median PFS of 13.93 months, while the tafasitamab plus rituximab plus lenalidomide arm reported a median PFS of 22.37 months. Additionally, Kaplan-Meier estimates of PFS by investigator assessment, using the Lugano 2014 criteria, were reported for up to 2 years. In the placebo plus rituximab plus lenalidomide arm, probabilities were 31.8 percent, 78.2 percent, 54.0 percent, and 38.5 percent. In the tafasitamab plus rituximab plus lenalidomide arm, probabilities were 79.0 percent and 41.7 percent.

All values presented are sourced from primary registry reporting; individual papers should be consulted for clinical decisions.

All Tafasitamab publications (25)

2026 (4 papers)

  1. Anti-CD19 antibody tafasitamab therapy for relapsed or refractory diffuse large B-cell lymphoma: a case series.
    You J, Chen W, Yan Z, et al. · Anticancer Drugs · 2026 · Derived
    PubMed: PMID 41176775 · NCT05552937
  2. Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial.
    Sehn LH, Hübel K, Luminari S, et al. · Lancet · 2026 · Derived
    PubMed: PMID 41360064 · NCT04680052 (InMIND) · Lymphoma, B-Cell, Marginal Zone
  3. International Prognostic Models as Tools for Selection of Higher-risk Trial-eligible Patients With Diffuse Large B-Cell lymphoma.
    Jelicic J, Juul-Jensen K, Bukumiric Z, et al. · Clin Lymphoma Myeloma Leuk · 2026 · Derived
    PubMed: PMID 40993016 · NCT04824092 (frontMIND) · Lymphoma, Large B-Cell, Diffuse
  4. Tafasitamab as Monotherapy or in Combination in Japanese Patients With B-Cell Non-Hodgkin Lymphoma: Results From the Phase 1b J-MIND Study.
    Izutsu K, Fukuhara N, Yuda J, et al. · Cancer Sci · 2026 · Derived
    PubMed: PMID 41563911 · NCT04661007 (J-MIND) · Lymphoma, Large B-Cell, Diffuse

2025 (1 paper)

  1. Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
    Roschewski M, Kurtz DM, Westin JR, et al. · J Clin Oncol · 2025 · Derived
    PubMed: PMID 40802906 · NCT04134936 · Lymphoma, Large B-Cell, Diffuse

2024 (1 paper)

  1. Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.
    Duell J, Abrisqueta P, Andre M, et al. · Haematologica · 2024 · Derived
    PubMed: PMID 37646664 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse

2023 (4 papers)

  1. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma.
    Westin J, Davis RE, Feng L, et al. · J Clin Oncol · 2023 · Derived
    PubMed: PMID 35952327 · NCT04978584 · Lymphoma, Large B-Cell, Diffuse
  2. Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
    Belada D, Kopeckova K, Bergua Burgues JM, et al. · Blood · 2023 · Derived
    PubMed: PMID 37369099 · NCT04134936 · Lymphoma, Large B-Cell, Diffuse
  3. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
    Eichhorst B, Niemann CU, Kater AP, et al. · N Engl J Med · 2023 · Background
    PubMed: PMID 37163621 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse
  4. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
    Derigs P, Bethge WA, Krämer I, et al. · Transplant Cell Ther · 2023 · Background
    PubMed: PMID 37709204 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse

2022 (7 papers)

  1. CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study.
    Duell J, Obr A, Augustin M, et al. · Leuk Lymphoma · 2022 · Trial result
    PubMed: PMID 34779360 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse
  2. RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
    Zinzani PL, Rodgers T, Marino D, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 34433649 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse
  3. Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
    Staber PB, Jurczak W, Greil R, et al. · Leuk Lymphoma · 2022 · Derived
    PubMed: PMID 34414843 · NCT02639910 (COSMOS) · Leukemia, Lymphocytic, Chronic, B-Cell
  4. Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study.
    Nowakowski GS, Yoon DH, Peters A, et al. · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35674661 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse
  5. Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls.
    Cherng HJ, Westin JR · Clin Cancer Res · 2022 · Derived
    PubMed: PMID 35861632 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse
  6. Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches.
    Gu T, Zhu M, Huang H, et al. · J Zhejiang Univ Sci B · 2022 · Background
    PubMed: PMID 36226535 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse
  7. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis.
    Di Blasi R, Le Gouill S, Bachy E, et al. · Blood · 2022 · Background
    PubMed: PMID 36122385 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse

2021 (2 papers)

  1. Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Duell J, Maddocks KJ, González-Barca E, et al. · Haematologica · 2021 · Trial result
    PubMed: PMID 34196165 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse
  2. Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
    Caimi PF, Ai W, Alderuccio JP, et al. · Lancet Oncol · 2021 · Background
    PubMed: PMID 33989558 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse

2020 (2 papers)

  1. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.
    Salles G, Duell J, González Barca E, et al. · Lancet Oncol · 2020 · Trial result
    PubMed: PMID 32511983 · NCT02399085 (L-MIND) · Lymphoma, Large B-Cell, Diffuse
  2. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
    Sehn LH, Herrera AF, Flowers CR, et al. · J Clin Oncol · 2020 · Background
    PubMed: PMID 31693429 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse

2018 (1 paper)

  1. Leveraging natural killer cells for cancer immunotherapy.
    Grossenbacher SK, Aguilar EG, Murphy WJ, et al. · Immunotherapy · 2018 · Background
    PubMed: PMID 28472904 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse

2016 (1 paper)

  1. Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
    Byrd JC, Harrington B, O'Brien S, et al. · N Engl J Med · 2016 · Background
    PubMed: PMID 26641137 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse

2010 (1 paper)

  1. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects.
    Olson JA, Leveson-Gower DB, Gill S, et al. · Blood · 2010 · Background
    PubMed: PMID 20233969 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse

2002 (1 paper)

  1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
    Coiffier B, Lepage E, Briere J, et al. · N Engl J Med · 2002 · Background
    PubMed: PMID 11807147 · NCT07225439 · Lymphoma, Large B-Cell, Diffuse

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).